Technical Analysis for NNVC - NanoViricides, Inc.

Grade Last Price % Change Price Change
grade F 0.1869 -5.13% -0.01
NNVC closed down 5.13 percent on Wednesday, September 18, 2019, on 1.16 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NNVC trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
New 52 Week Closing Low Bearish -5.13%

Older signals for NNVC ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.
Medicine Medical Specialties Infectious Diseases Infection Influenza HIV HIV/Aids Antiviral Drug Virus Herpes Simplex Virus Rabies Viral Diseases Ebola Herpes Simplex Epidemiology Genital Herpes Human Influenza Viral Disease
Is NNVC a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 0.68
52 Week Low 0.1605
Average Volume 112,555
200-Day Moving Average 0.2742
50-Day Moving Average 0.2256
20-Day Moving Average 0.2113
10-Day Moving Average 0.2102
Average True Range 0.0221
ADX 27.46
+DI 8.4221
-DI 24.1691
Chandelier Exit (Long, 3 ATRs ) 0.1752
Chandelier Exit (Short, 3 ATRs ) 0.2268
Upper Bollinger Band 0.2332
Lower Bollinger Band 0.1894
Percent B (%b) -0.06
BandWidth 20.728822
MACD Line -0.008
MACD Signal Line -0.0058
MACD Histogram -0.0022
Fundamentals Value
Market Cap 11.83 Million
Num Shares 63.3 Million
EPS -0.17
Price-to-Earnings (P/E) Ratio -1.10
Price-to-Sales 0.00
Price-to-Book 3.04
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.21
Resistance 3 (R3) 0.21 0.21 0.21
Resistance 2 (R2) 0.21 0.20 0.20 0.20
Resistance 1 (R1) 0.20 0.20 0.19 0.19 0.20
Pivot Point 0.19 0.19 0.19 0.19 0.19
Support 1 (S1) 0.18 0.18 0.18 0.18 0.17
Support 2 (S2) 0.18 0.18 0.17 0.17
Support 3 (S3) 0.17 0.18 0.17
Support 4 (S4) 0.16